Targeted therapies for the systemic treatment of advanced hepatocellular carcinoma

Fiona Chionh, A. Azad, Jonathan Cebon

Research output: Contribution to journalReview ArticleResearchpeer-review


Advanced hepatocellular carcinoma is the third most common cause of cancer-related mortality worldwide. Systemic therapy has historically had limited efficacy; however, targeted therapies offer promise in improving patient outcomes. Recently, two pivotal phase III randomized double-blind trials of the oral multi-tyrosine kinase inhibitor sorafenib compared with placebo demonstrated a survival benefit in advanced hepatocellular carcinoma. Other targeted agents have also shown promising results in early-phase trials. This review examines the current knowledge about targeted therapies in advanced hepatocellular carcinoma and addresses some of the key issues for future research in this disease.

Original languageEnglish
Pages (from-to)81-94
Number of pages14
JournalAsia Pacific Journal of Oncology and Hematology
Issue number1
Publication statusPublished - Feb 2010
Externally publishedYes


  • Angiogenesis
  • Growth factor
  • Growth factor receptor
  • Hepatocellular carcinoma
  • Signal transduction pathways
  • Sorafenib
  • Targeted therapies

Cite this